Joseph Nixon
Director Financiero/CFO en Locus Biosciences, Inc. .
Perfil
Joseph Nixon is currently the Director at Bioaesthetics Corp.
and the Chief Financial Officer at Locus Biosciences, Inc. He received his undergraduate degree from Case Western Reserve University and his MBA from Harvard Business School.
Cargos activos de Joseph Nixon
| Empresas | Cargo | Inicio |
|---|---|---|
Bioaesthetics Corp.
 Bioaesthetics Corp. Miscellaneous Commercial ServicesCommercial Services Bioaesthetics Corp. provides biotechnology health care services. The company was founded by Nicholas C. Pashos and is headquartered in New Orleans, LA. | Director/Miembro de la Junta | 23/08/2023 |
Locus Biosciences, Inc.
 Locus Biosciences, Inc. Packaged SoftwareTechnology Services Locus Biosciences, Inc. develops CRISPR-engineered precision antibacterial products for antibiotic-resistant bacterial infections and microbiome-related disease. The firm offers CRISPR-engineered bacteriophage and CRISPR-Cas3 phage. The company was founded by Charles Gersbach, Dave Ousterout, Chase Beisel, Paul M. Garofolo, Nick Taylor, and Rodolphe Barrangou in 2015 and is headquartered in Morrisville, NC. | Director Financiero/CFO | - |
Formación de Joseph Nixon.
| Case Western Reserve University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Bioaesthetics Corp.
Bioaesthetics Corp. Miscellaneous Commercial ServicesCommercial Services Bioaesthetics Corp. provides biotechnology health care services. The company was founded by Nicholas C. Pashos and is headquartered in New Orleans, LA. | Commercial Services |
Locus Biosciences, Inc.
Locus Biosciences, Inc. Packaged SoftwareTechnology Services Locus Biosciences, Inc. develops CRISPR-engineered precision antibacterial products for antibiotic-resistant bacterial infections and microbiome-related disease. The firm offers CRISPR-engineered bacteriophage and CRISPR-Cas3 phage. The company was founded by Charles Gersbach, Dave Ousterout, Chase Beisel, Paul M. Garofolo, Nick Taylor, and Rodolphe Barrangou in 2015 and is headquartered in Morrisville, NC. | Technology Services |
- Bolsa de valores
- Insiders
- Joseph Nixon